Precision

Stephanie Cutter Joins Equality Health Board of Directors

Retrieved on: 
木曜日, 10月 19, 2023
President Clinton, Stephanie Cutter, Democratic National Convention, Precision, Public policy, Health, Equalize Health, Georgetown University Law Center, Government, White House, Cutter, Lisa Ellis (executive producer), Public opinion, News, ABC News, Marketing, Medicaid, White, Democrat, GQ, CNN, Executive producer, Crossfire, Smith College, The New York Times, Senate, Management, Politico

PHOENIX, Oct. 19, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, today announced the appointment of Stephanie Cutter to its board of directors. Cutter is a highly respected communications and campaign strategist with a successful track record of creating and executing national campaigns to enhance brands and reputations, manage crises, and shape critical public policy issues. She has worked with top political figures and Fortune 500 corporations, and played key roles in high-profile national events.

Key Points: 
  • PHOENIX, Oct. 19, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, today announced the appointment of Stephanie Cutter to its board of directors.
  • "I've spent my career working to improve access to quality health care for all Americans," said Stephanie Cutter.
  • "Equality Health's innovative approach to working with Medicaid providers to deliver better health outcomes and lower costs has the ability to transform our health care system and improve the health of millions of Americans.
  • A resident of Washington, D.C., Cutter is a graduate of Smith College and Georgetown University Law Center.

Meet Dell's newest workstation - featuring 96 cores

Retrieved on: 
木曜日, 10月 19, 2023
AEC, Precision, Life, AMD, TB, Architecture, IDC, Wi-Fi, Organization, Research, Engineering, Multimedia, Memory, NVIDIA, Trusted Platform Module, Dell, Virtual reality, Machine learning, CPU, TPM, AI, Cleveland Clinic, Dell Precision, PCI Express, DDR5, Workload, Dell Technologies, Video game, Medical device, Online shopping, Aluminium

ROUND ROCK, Texas, Oct. 19, 2023 /PRNewswire/ -- Here at Dell Technologies, we are big believers that the workstation industry has always been fast-paced and exciting. We've had a front row seat for more than 25 years helping creators, engineers, architects, researchers and more bring their ideas to life and make an impact on the world. Workstations have played a critical role here, viewed as a necessary tool to make the impossible possible. Now the world is buzzing with AI and generative AI (GenAI), and workstations are in the spotlight in a different way.

Key Points: 
  • That's why we're especially excited to introduce the new Precision 7875 Tower featuring AMD Ryzen™ Threadripper™ PRO 7000 WX-Series processors.
  • It's Dell's most scalable and powerful AMD processor-based workstation ever.4
    Designed for engineers, architects, creatives and product designers, the Precision 7875 Tower is a multithreaded computing workstation for demanding professional applications.
  • With up to 96 cores, the Precision 7875 Tower has the most cores of any single socket Dell Precision workstation.5
    The Precision 7875 Tower is a performance powerhouse.
  • The workstation can support a variety of AI functions, such as model training, GenAI, machine learning and more.

Precision Neuroscience Acquires U.S. Manufacturing Facility and Receives FDA Breakthrough Device Designation

Retrieved on: 
木曜日, 10月 5, 2023
Foot, Acquisition, Food, MEMS, Paralysis, BCI, Brain, ISO, Precision, Workforce, Bio-MEMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Electrode, Sale, Computer, Medical device, Medical imaging

Further, the company also announced that its system has been awarded Breakthrough Device designation from the U.S. Food and Drug Administration.

Key Points: 
  • Further, the company also announced that its system has been awarded Breakthrough Device designation from the U.S. Food and Drug Administration.
  • Precision BioMEMS retained the facility’s team, which has deep expertise in both biomedical and general-purpose MEMS manufacturing.
  • In addition to its work for Precision, Precision BioMEMS will continue to operate as a foundry serving other cutting-edge companies in the United States.
  • “High precision microfabrication is critical to building powerful brain–computer interfaces, and it will play an increasingly important role in medical device manufacturing going forward.

Charter Communications Forges Partnership with Precision Optical Technologies to Advance Distributed Access Architectures

Retrieved on: 
水曜日, 10月 11, 2023
Partnership, DWDM, Engineering, DAA, Charter Communications, Charter, Precision, SVP, Telecommunications

ROCHESTER, N.Y., Oct. 11, 2023 /PRNewswire/ -- Precision Optical Technologies, Inc ., a recognized leader in optical networking technologies, proudly announces its multi-year strategic partnership with Charter Communications, Inc.

Key Points: 
  • ROCHESTER, N.Y., Oct. 11, 2023 /PRNewswire/ -- Precision Optical Technologies, Inc ., a recognized leader in optical networking technologies, proudly announces its multi-year strategic partnership with Charter Communications, Inc.
  • This partnership further solidifies Precision OT's reputation as a trusted partner and solutions provider in the telecommunications and optical technology sectors.
  • "We are pleased that Charter Communications has chosen Precision OT as a trusted technology partner to deploy cutting-edge optical networking solutions," said Keith Habberfield, SVP of Sales & Marketing at Precision OT.
  • For more information about Precision Optical Technologies, Inc., and its innovative solutions, please visit www.precisionot.com .

Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal Antibody, NEO-201, For the Treatment of Human Carcinomas

Retrieved on: 
月曜日, 10月 2, 2023
Head and neck cancer, Clinical trial, Cervical cancer, Cancer, Immunotherapy, Endometrial cancer, NSCLC, Precision, Regulatory T cell, Patent, Patient, Immunoglobulin G, Conference, Safety, Disease, Pharmaceutical industry, Pembrolizumab

NEO-201 is a humanized IgG1 monoclonal antibody with multiple mechanisms of action.

Key Points: 
  • NEO-201 is a humanized IgG1 monoclonal antibody with multiple mechanisms of action.
  • It has been shown previously to kill cancer cells expressing its target (truncated glycans) which is expressed in numerous cancers; however, it does not bind to most normal tissues.
  • Data from the ongoing Phase 2 trial was recently presented at CRI-ENCI-AACR 7th International Cancer Immunotherapy Conference Sept 22, 2023, Milan, Italy.
  • Additional data regarding the effects of NEO-201 on reducing gMDSCs will be presented at the upcoming SITC Annual Meeting in San Diego in early November.

Precision OT Announces Cutting-Edge ASIC Technology to Enable Tunables and Extended Reach

Retrieved on: 
月曜日, 10月 2, 2023
Education minister, DWDM, AEG, ESD, ASIC, SCTE, Precision, DOCSIS, Electronics, Software, Telescopic sight

With a focus on consistently developing new technologies in integrated photonics, electronics and software, Precision OT's Advanced Engineering Group (AEG) has created the new ASIC to enable cutting-edge technologies such as 25G tunable transceivers.

Key Points: 
  • With a focus on consistently developing new technologies in integrated photonics, electronics and software, Precision OT's Advanced Engineering Group (AEG) has created the new ASIC to enable cutting-edge technologies such as 25G tunable transceivers.
  • Although there are many processing tools available for compensation, Precision OT's pioneering pre-distortion technique stands out, offering unique advantages.
  • Enter Precision OT's groundbreaking pre-compensation ASIC to extend the reach of tunable 25G out to 40km and beyond.
  • Precision OT will demonstrate the technology in a TSFP28-40(I) (tunable 25G extended reach module) product demonstration at the SCTE Cable-Tec Expo, held October 16-19 in Denver, Colorado .

Consider It Flowers Launches CannaBitters as an Innovative Beverage Line

Retrieved on: 
水曜日, 9月 27, 2023
Limonene, Cannabis, Flower, THC, Magic, Smoking, Glass, Empowerment, Water, Precision, Terpene, Drug

In the latest development, the company announces the launch of CannaBitters, an innovative product that is set to redefine the way enthusiasts and connoisseurs experience the effects of cannabis.

Key Points: 
  • In the latest development, the company announces the launch of CannaBitters, an innovative product that is set to redefine the way enthusiasts and connoisseurs experience the effects of cannabis.
  • CannaBitters is poised to transform the cannabis beverage market with its innovative approach to delivering the authentic cannabis experience.
  • CannaBitters by Consider It Flowers boasts several key features such as no sugar, no calories and no carbs making it a guilt-free way to enjoy the cannabis experience.
  • Consider It Flowers invites its potential buyers to explore the world of CannaBitters and experience the enthralling effects of Lemon Sherbet terpenes.

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

Retrieved on: 
水曜日, 9月 27, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Precision BioSciences, Patent, MELAS, CRISPR, DNA, University, Mitochondrion, Gene editing, RNA, Doctor of Philosophy, Precision, Disorder, Mitochondrial myopathy, Cell biology, Patient, Anatomy, Entrepreneurship, Lactic acidosis, Vaccine, Neurology

18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.” Once issued, the patent arising from this application will have a standard expiration date in April 2042.

Key Points: 
  • 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.” Once issued, the patent arising from this application will have a standard expiration date in April 2042.
  • The allowed composition of matter claims in this U.S. application encompass a mitochondria-targeted ARCUS nuclease (mitoARCUS) that is designed to specifically target, cleave, and eliminate mutant mitochondrial DNA comprising an m.3243A>G mutation.
  • Precision recently announced PBGENE-PMM, the Company’s clinical candidate targeting mutant mitochondrial DNA, as a potentially first-in-class opportunity for treatment of m.3243 associated primary mitochondrial myopathy.
  • Utilizing the claimed mitoARCUS nuclease, PBGENE-PMM is designed to target and eliminate mutant mitochondrial DNA, allowing for repopulation by wild-type mitochondrial DNA and restoration of mitochondrial function.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
火曜日, 9月 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
火曜日, 9月 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.